Conduct↦Quality and Risk↦Risk Review↦Procedures
What is it? Why is it important?
Risk review is an integral part of the study`s risk strategy during study conduct.
During risk reviews, risk control-measures are re-evaluated to ensure they remain applicable and effective. The implementation of risk control-measures were initially planed based on threats to the study`s Critical to Quality (CtoQ) factors. (e.g. participant safety and rights, data quality, regulatory (Swiss law) and protocol compliance)
Questions to ask during risk reviews:
- Have all CtoQ factors, in need of risk control-measures, been correctly identified
- Have risks threatening the study`s CtoQ been correctly identified
- How effective are the originally planned risk control-measures? Do they need improvement, or must they be replaced? Are measures still relevant with respect to emerging knowledge and expertise?
- Is there an occurrence of new risks?
- Have previously identified risks become less relevant?
- Is study staff properly trained on risk-responsibilities and the implementation of risk control-measures?
- Has the risk review been properly documented (e.g. in a Risk Assessment Form (RAF))
More
EXAMPLE OF A RISK REVIEW AND ITS RE-EVALUATION PROCESS
Protocol requirement (a CtoQ factor): Lab analysis must be performed on fasting blood samples.
Risk: participants are not fasting
1st Risk control-measure: participants are informed at study inclusion regarding fasting state at blood draw
- 1st Periodic risk review: 25% of participants present with no fasting blood at blood draw
- 1st Risk re-evaluation and documentation: 25% surpasses predefined tolerance limit of 10%. Risk control-measures must be improved
2nd Adaptation of risk control-measures: Participants are reminded by SMS on the evening before blood draw regarding fasting state at blood draw
- 2nd Periodic risk review: 13% of participants present with no fasting blood at blood draw
- 2nd Risk re-evaluation and documentation: 13% acceptable with given conditions. Additional risk control-measures are not feasible or too costly if implemented. An evaluation must ensue regarding the need for a protocol amendment
What do I need to do?
- Based on the risk strategy defined by the SP-INV, implement applicable risk reviews
- Promote and facilitate the interaction between those implementing risk control-measures, and those deciding on what risk control-measures to implement. Only with a robust feedback-loop can it be guaranteed that risk control-measures remain appropriate and effective
- Keep vigilance regarding deviations from predefined risk tolerance limits
- Automatically trigger a risk review:
- If a risk deviates from a predefined quality tolerance limit
- After implementing new risk control-measures
Tasks during risk reviews include to:
- Collect staff feedback on implemented risk control-measures (i.e. schedule regular staff meetings focusing on risk management)
- Discuss and decide, together with risk-responsible staff, whether risk control-measures must be adapted, improved, or even deleted
- Review risk tolerance limits, and decide whether they must be adapted?
- Review and approve the documentation regarding risk reviews. This ensures that the study remains inspection ready (e.g. Swissmedic inspection)
More
The documentation of risk reviews should include:
- Risk implication and the ongoing effectiveness of risk control-measures, based on emerging knowledge and expertise. Which risk control-measures were effective, and which one did not work?
- The inclusion and description of newly identified risks and/or CtoQ factors
- The use and management of automatic triggers (i.e. risk deviation from predefined quality tolerance limits)
- Information flow between those implementing risk control-measures, and those deciding what control-measures to implement
By documenting the study`s ongoing risk management, lessons learned can be used for optimal risk management in subsequent studies.
Where can I get help?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
References
ICH GCP E6(R3) – see in particular guidelines
- 3.10 Quality management
- 3.10.1.2 Risk evaluation
- 3.10.1.5 Risk review
ISO 31000 (access liable to costs) – see in particular section
- Risk management: Principles and guidelines